Insider Trading History of Bencherif Merouane

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) by Bencherif Merouane since 2009. The trader's CIK number is 1295831. At the time of the last reporting, Bencherif Merouane was the VP, Preclinical Rese of Catalyst Biosciences, Inc.. (stock ticker symbol CBIO). Also see all insider trading activities at Catalyst Biosciences, Inc..


Yearly summary of insider trading at Catalyst Biosciences, Inc. (TRGT) by Bencherif Merouane

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2012 TRGT 0 $0 0 $0 15,938 $46,698
2011 TRGT 0 $0 53,003 $1,437,735 53,003 $236,780
2010 TRGT 0 $0 112,936 $2,432,359 105,201 $483,897
2009 TRGT 0 $0 120,007 $1,666,568 120,007 $530,807


Insider trading of Catalyst Biosciences, Inc. (TRGT) by Bencherif Merouane

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2012-05-18 TRGT Option Ex 15,938 2.93 46,698
2011-01-18 TRGT Sale 22,800 27.17 619,476
2011-01-19 TRGT Sale 30,203 27.09 818,259
2011-01-18 TRGT Option Ex 22,800 5.55 126,540
2011-01-19 TRGT Option Ex 30,203 3.65 110,240
2010-12-10 TRGT Sale 32,093 24.05 771,965
2010-12-10 TRGT Option Ex 32,093 5.66 181,742
2010-01-15 TRGT Sale 73,108 20.51 1,499,445
2010-01-15 TRGT Option Ex 73,108 4.13 302,155
2010-01-04 TRGT Sale 7,735 20.81 160,949
2009-12-16 TRGT Option Ex 15,532 8.51 132,177
2009-12-16 TRGT Sale 15,532 21.93 340,663
2009-12-15 TRGT Sale 8,056 22.18 178,722
2009-12-14 TRGT Sale 12,935 22.45 290,351
2009-12-15 TRGT Option Ex 8,056 8.51 68,556
2009-12-14 TRGT Option Ex 12,935 5.72 73,988
2009-07-28 TRGT Option Ex 41,213 2.59 106,659
2009-07-28 TRGT Sale 41,213 10.39 428,120
2009-07-27 TRGT Option Ex 42,271 3.54 149,427
2009-07-27 TRGT Sale 42,271 10.14 428,712

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Bencherif Merouane (VP, Preclinical Rese of Catalyst Biosciences, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.